Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Intellia Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2016 Unicorn

A leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases

Valuation
$1.25B
Market cap · May/2026
Revenue
$68M
Latest reported FY

Investors

8 investors on Intellia Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Series B+ 4 investors entered at this stage
OrbiMed
University of California
Berkeley
Foresite Capital

Global footprint

Where Intellia Therapeutics has talent and traffic

AI talent share
0.7% of workforce is AI talent
(3 of 452 staff)
Core AI10.22%
Other AI20.44%
Non-AI workforce44999.34%
Workforce by country
5 countries with
team presence
🇺🇸 United States98.7%
🇦🇷 Argentina0.6%
🇪🇸 Spain0.3%
🇬🇧 United Kingdom0.3%
🇩🇪 Germany0.3%
5 countries shown
Web traffic by country
70K monthly visits
across markets
🇺🇸 United States40.9%
🇪🇸 Spain34.4%
🇮🇳 India8.7%
🇬🇧 United Kingdom3.6%
🇨🇦 Canada3.1%
Top 5 markets shown

Patent intelligence

$60M patent portfolio · 81 active families

Estimated portfolio value
$60M
4.8% of market cap · 33.6× smaller than top peer Ablynx ($2B)
81 active patent families
Where Intellia Therapeutics innovates Molecular biologyGenome editingBioinformaticsCell biologyCell

Where Intellia Therapeutics concentrates vs peers

Each axis is a top-10 topic across Intellia Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Intellia Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Intellia Therapeutics appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Intellia Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Intellia Therapeutics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Intellia Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Intellia Therapeutics

        An AI-synthesized read of the highest-engagement posts about Intellia Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Intellia Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.